BIOATLA, INC. Accounts Payable
BIOATLA, INC. (BCAB) had Accounts Payable of $12.71 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable, Current $12.71M.
- 2026-03-31: Accounts Payable, Current $12.12M.
- 2025-12-31: Accounts Payable, Current $8.19M.
- 2025-09-30: Accounts Payable, Current $5.85M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $12.71M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $12.12M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $8.19M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $5.85M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $4.64M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $4.70M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.90M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.93M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.36M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $3.45M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $3.82M 10-K · filed 2025-03-28 |
| 2023-09-30 | $6.29M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $2.97M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $8.05M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $4.23M 10-K · filed 2024-03-26 |
| 2022-09-30 | $3.70M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $4.82M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.20M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.18M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.55M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $1.28M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $2.50M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $2.46M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |